Cannabinoid receptors as new targets of antifibrosing strategies during chronic liver diseases.
about
Targeting the endocannabinoid system with cannabinoid receptor agonists: pharmacological strategies and therapeutic possibilitiesThe diverse CB1 and CB2 receptor pharmacology of three plant cannabinoids: delta9-tetrahydrocannabinol, cannabidiol and delta9-tetrahydrocannabivarinThe role of endocannabinoids system in fatty liver disease and therapeutic potentialsMechanisms of hepatic fibrogenesisThe plant cannabinoid Delta9-tetrahydrocannabivarin can decrease signs of inflammation and inflammatory pain in mice.CB2 Cannabinoid receptors as a therapeutic target-what does the future hold?The endocannabinoid system as a key mediator during liver diseases: new insights and therapeutic openingsCannabinoid receptor type I modulates alcohol-induced liver fibrosis.Endocannabinoids and cannabinoid receptors in ischaemia-reperfusion injury and preconditioningEndocannabinoids and liver disease. III. Endocannabinoid effects on immune cells: implications for inflammatory liver diseasesCB2 receptors as new therapeutic targets for liver diseasesTargeting the endocannabinoid system: to enhance or reduce?Ligands that target cannabinoid receptors in the brain: from THC to anandamide and beyond.Emerging strategies for exploiting cannabinoid receptor agonists as medicines.Nonalcoholic fatty liver disease: a challenge for pediatricians.Bisdemethoxycurcumin Induces apoptosis in activated hepatic stellate cells via cannabinoid receptor 2.Beneficial paracrine effects of cannabinoid receptor 2 on liver injury and regeneration.Daily cannabis and reduced risk of steatosis in human immunodeficiency virus and hepatitis C virus co-infected patients (ANRS CO13-HEPAVIH).Cannabinoid receptor 2 counteracts interleukin-17-induced immune and fibrogenic responses in mouse liver.Curcumin and hemopressin treatment attenuates cholestasis-induced liver fibrosis in rats: role of CB1 receptors.
P2860
Q24623282-9678B2C4-32B8-43AF-AF9F-21CDFDE12AA6Q24643876-BF080CAE-8DEB-4005-A21B-F1EE5037D6B2Q27009466-E8C371BF-AE33-4986-B6FB-CEE3932E7F15Q29619336-F25BEDFB-3064-41C5-A39C-E755AC954B52Q34098266-D03A5578-7049-4B48-9544-1D62B395240FQ34186015-558C87C5-0B03-4C71-AE11-3588CF89A9B2Q35193292-7582DD4F-1192-44CE-B64D-2E89E7BECE1EQ35876795-5EABED24-9777-41DE-B455-E1739BB13F4CQ36416372-59CB6CA7-87F9-40F1-A972-DFA4EC4BCE89Q36647969-F0E7441C-E623-4280-A94E-1D2F05EE84E7Q36977545-65F3E2FD-98A5-4821-B65B-910AB235E0E4Q37150745-F54B5A2C-CDFA-46A7-9839-A65FE8D7EE24Q37164807-BEF86851-4E37-496E-8508-8A565E5D0521Q37230665-D8D6FF0F-68A0-46E0-B0CE-6AF179E5F3A6Q37788538-53AF2E3C-ED85-4053-B4C3-10932A487F57Q38919351-180A702C-E895-48AA-B0CA-D54782862C54Q40001901-767915C9-89FF-4A7D-BED9-78FF5D57D4E0Q41923080-BE313729-C8F0-4130-A52D-7E80FAAD812FQ50867754-17873283-ECD4-464F-A3F7-5B2F00C07479Q53308324-8B356B87-0EE3-4535-8625-9884B3456C1E
P2860
Cannabinoid receptors as new targets of antifibrosing strategies during chronic liver diseases.
description
2007 nî lūn-bûn
@nan
2007年の論文
@ja
2007年論文
@yue
2007年論文
@zh-hant
2007年論文
@zh-hk
2007年論文
@zh-mo
2007年論文
@zh-tw
2007年论文
@wuu
2007年论文
@zh
2007年论文
@zh-cn
name
Cannabinoid receptors as new t ...... during chronic liver diseases.
@ast
Cannabinoid receptors as new t ...... during chronic liver diseases.
@en
type
label
Cannabinoid receptors as new t ...... during chronic liver diseases.
@ast
Cannabinoid receptors as new t ...... during chronic liver diseases.
@en
prefLabel
Cannabinoid receptors as new t ...... during chronic liver diseases.
@ast
Cannabinoid receptors as new t ...... during chronic liver diseases.
@en
P2093
P2860
P921
P1476
Cannabinoid receptors as new t ...... during chronic liver diseases.
@en
P2093
Ariane Mallat
Fatima Teixeira-Clerc
Vanessa Deveaux
P2860
P304
P356
10.1517/14728222.11.3.403
P407
P577
2007-03-01T00:00:00Z